Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2002

View Archived Issues

U.S. launch of new injectable carbapenem announced by Merck

Bextra now available for prescription in the U.S.

Evidence of antipsoriatic activity obtained in phase II trial of topical alicaforsen

Newly introduced Elidel cream associated with reduced disease flares and corticosteroid use

Xanelim pivotal results discussed at the AAD meeting; BLA may be filed this summer

Novel class of analgesics --VR1 blockers-- discovered by Spanish researchers

IL-6 exerts central antiobesity effects in rodents

Cubist and Novartis extend antiinfective drug discovery collaboration

Caprion and McGill University to collaborate on proteomics research

FlowGuard approved in U.S.

NDA filed for acamprosate for the treatment of alcohol dependency

Initiation of phase II trial of MVA-HPV-IL-2 in cervical intraepithelial neoplasia

FDA approves new indication for Plavix in acute coronary syndrome

Schering initiates phase III BENEFIT study of Betaferon/Betaseron

MS-818 accelerates early muscle regeneration and enhances recovery postsurgery

ImClone and partners discuss resubmission of Erbitux BLA with FDA

Access acquires targeted therapeutic division of Biotech Australia

Once- or twice-yearly i.v. zoledronic acid effective in postmenopausal osteoporosis

Tissue-specific selfinactivating gene therapy described by UAB Research Foundation

Ranbaxy designs compounds effective against Gram-positive and anaerobic bacteria

Compounds with high affinity for the alpha5 subunit of GABA-A receptors

Phosphate esters of peptidomimetic compounds for treatment of HIV infection

American Cyanamid prepares new inhibitors of TACE and other MMPs

Inhibitors of factor Xa with utility in thrombosis associated with cardiovascular disorders

DuPont discloses compounds for the treatment of anxiety and depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...